Jeannie-Marie S. Leoutsakos

Jeannie-Marie S. Leoutsakos

Auto-generated profile, based on publicly available information

Jeannie-Marie S. Leoutsakos

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2019 in Critical Care
Verified
Journal Article
Open access
PDF file
MHMegan M. Hosey
Megan M. Hosey
JLJeannie-Marie S. Leoutsakos
Jeannie-Marie S. Leoutsakos
XLXimin Li
Ximin Li
VDVictor D. Dinglas
Victor D. Dinglas
OBO. Joseph Bienvenu
O. Joseph Bienvenu
KNKarin J. Neufeld
Karin J. Neufeld
Posttraumatic stress disorder (PTSD) symptoms are common in acute respiratory distress syndrome (ARDS) survivors. Brief screening instruments are needed for clinical and research purposes. We evaluated internal consistency, external construct, and criterion validity of the Impact of Event Scale-6 (IES-6; 6 items) compared to the original Impact of Event Scale—Revised (IES-R; 22 items) and to the Clinician Administered PTSD Scale (CAPS) reference standard evaluation in ARDS survivors. This study is a secondary analysis from two independent multi-site, prospective studies of ARDS survivors. Measures of internal consistency, and external construct and criterion validity were evaluated. A total of 1001 ARDS survivors (51% female, 76% white, mean (SD) age 49 (14) years) were evaluated. The IES-6 demonstrated internal consistency over multiple time points up to 5 years after ARDS (Cronbach’s alpha = 0.96; 95% confidence interval (CI) 0.94 to 0.97). The IES-6 demonstrated stronger correlations with related constructs (e.g., anxiety and depression; |r| = 0.32 to 0.52) and weaker correlations with unrelated constructs (e.g., physical function and healthcare utilization measures (|r| = 0.02 to 0.27). Criterion validity evaluation with the CAPS diagnosis of PTSD in a subsample of 60 participants yielded an area under receiver operating characteristic curve (95% CI) of 0.93 (0.86, 1.00), with an IES-6 cutoff score of 1.75 yielding 0.88 sensitivity and 0.85 specificity. The IES-6 is reliable and valid for screening for PTSD in ARDS survivors and may be useful in clinical and research settings.

1 January 2021 in NeuroImage: Clinical
Verified
Journal Article
Open access
JTJennifer Tremblay-Mercier
Jennifer Tremblay-Mercier
CMCécile Madjar
Cécile Madjar
SDSamir Das
Samir Das
ABAlexa Pichet Binette
Alexa Pichet Binette
SDStephanie O.M. Dyke
Stephanie O.M. Dyke
JBJohn C.S. Breitner
John C.S. Breitner
To move Alzheimer Disease (AD) research forward it is essential to collect data from large cohorts, but also make such data available to the global research community. We describe the creation of an open science dataset from the PREVENT-AD (PResymptomatic EValuation of Experimental or Novel Treatments for AD) cohort, composed of cognitively unimpaired older individuals with a parental or multiple-sibling history of AD. From 2011 to 2017, 386 participants were enrolled (mean age 63 years old ± 5) for sustained investigation among whom 349 have retrospectively agreed to share their data openly. Repositories are findable through the unified interface of the Canadian Open Neuroscience Platform and contain up to five years of longitudinal imaging data, cerebral fluid biochemistry, neurosensory capacities, cognitive, genetic, and medical information. Imaging data can be accessed openly at https://openpreventad.loris.ca while most of the other information, sensitive by nature, is accessible by qualified researchers at https://registeredpreventad.loris.ca. In addition to being a living resource for continued data acquisition, PREVENT-AD offers opportunities to facilitate understanding of AD pathogenesis.

19 June 2018 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
PDF file
JLJeannie-Marie S. Leoutsakos
Jeannie-Marie S. Leoutsakos
HYHaijuan Yan
Haijuan Yan
WAWilliam S. Anderson
William S. Anderson
WAWael F. Asaad
Wael F. Asaad
GBGordon Baltuch
Gordon Baltuch
CLConstantine G. Lyketsos
Constantine G. Lyketsos
Background: Given recent challenges in developing new treatments for Alzheimer dementia (AD), it is vital to explore alternate treatment targets, such as neuromodulation for circuit dysfunction. We previously reported an exploratory Phase IIb double-

10 May 2011 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PDF file
JLJeannie‐Marie S. Leoutsakos
Jeannie‐Marie S. Leoutsakos
BMBengt O. Muthen
Bengt O. Muthen
JBJohn C.S. Breitner
John C.S. Breitner
CLConstantine G. Lyketsos
Constantine G. Lyketsos

9 September 2015 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
JLJeannie-Marie S. Leoutsakos
Jeannie-Marie S. Leoutsakos
SFSarah N. Forrester
Sarah N. Forrester
CLConstantine.G. Lyketsos
Constantine.G. Lyketsos
GSGwenn S. Smith
Gwenn S. Smith
Background: A number of studies have linked neuropsychiatric symptoms to increase risk of dementia. Objective: To determine if risk of conversion to mild cognitive impairment or dementia among healthy controls varied as a function of their pattern o

3 November 2014 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PDF file
JLJeannie‐Marie S. Leoutsakos
Jeannie‐Marie S. Leoutsakos
SFSarah N. Forrester
Sarah N. Forrester
CCChristopher D. Corcoran
Christopher D. Corcoran
MNMaria C. Norton
Maria C. Norton
PRPeter V. Rabins
Peter V. Rabins
CLConstantine G. Lyketsos
Constantine G. Lyketsos